Street Poller Media and The Boom of the Street Interview Ad Industry 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
France Targets Shein, Temu With Fast-Fashion Fees 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Add as a preferred source on Google
SAINT LAURENT, Quebec, March 23, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2017 financial results after market close on March 29, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, March 29, 2018
Time: 4:30 p.m. EDT
Conference dial-in: (833) 211-3233
International dial-in: (647) 689-3955
Conference ID: 6786519
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations."
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
